Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2018 Nov 30. doi: 10.1111/liv.14014. [Epub ahead of print]

PMID:
30499631
2.

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users.

Major M, Gutfraind A, Shekhtman L, Cui Q, Kachko A, Cotler SJ, Hajarizadeh B, Sacks-Davis R, Page K, Boodram B, Dahari H.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.

PMID:
29997251
3.

Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models.

Kumberger P, Durso-Cain K, Uprichard SL, Dahari H, Graw F.

Viruses. 2018 Apr 17;10(4). pii: E200. doi: 10.3390/v10040200.

4.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

PMID:
29572897
5.

Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics.

Reinharz V, Dahari H, Barash D.

Math Biosci. 2018 Jun;300:1-13. doi: 10.1016/j.mbs.2018.03.011. Epub 2018 Mar 15.

PMID:
29550297
6.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

7.

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K.

PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.

8.

How to eliminate HCV in people who inject drugs in the USA.

Dahari H, Boodram B.

Lancet Infect Dis. 2018 Feb;18(2):134-135. doi: 10.1016/S1473-3099(17)30678-3. Epub 2017 Nov 15. No abstract available.

PMID:
29153267
9.

High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Network Members.

Boodram B, Hotton AL, Shekhtman L, Gutfraind A, Dahari H.

J Urban Health. 2018 Feb;95(1):71-82. doi: 10.1007/s11524-017-0185-7.

PMID:
28875410
10.

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H.

Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.

11.

End of treatment RNA-positive/sustained viral response in an individual with acute hepatitis C virus infection treated with direct-acting antivirals.

Shteyer E, Dahari H, Gafanovich I, Dery I, Wolf D, Cotler SJ, Lurie Y.

Therap Adv Gastroenterol. 2017 May;10(5):429-430. doi: 10.1177/1756283X17694808. Epub 2017 Feb 1. No abstract available.

12.

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.

13.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

World J Hepatol. 2016 Jul 18;8(20):858-62. doi: 10.4254/wjh.v8.i20.858.

14.

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K.

J Viral Hepat. 2016 Sep;23(9):708-17. doi: 10.1111/jvh.12551. Epub 2016 Jun 8.

15.

Resurrection of response-guided therapy for sofosbuvir combination therapies.

Dahari H, Halfon P, Cotler SJ.

J Hepatol. 2016 Sep;65(3):462-4. doi: 10.1016/j.jhep.2016.05.028. Epub 2016 May 27. No abstract available.

16.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.

17.

Cure prevents more than transmission of hepatitis C virus.

Dahari H, Cotler SJ, Feld JJ.

Hepatology. 2016 Sep;64(3):1003-4. doi: 10.1002/hep.28449. Epub 2016 Mar 7. No abstract available.

18.

Agent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C Infections.

Gutfraind A, Boodram B, Prachand N, Hailegiorgis A, Dahari H, Major ME.

PLoS One. 2015 Sep 30;10(9):e0137993. doi: 10.1371/journal.pone.0137993. eCollection 2015.

19.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.

20.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16.

21.

Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H.

J Virol. 2015 Jul;89(13):6551-61. doi: 10.1128/JVI.00016-15. Epub 2015 Apr 1.

22.

Reply: To PMID 25098971.

Guedj J, Canini L, Cotler S, Dahari H.

Hepatology. 2015 Jun;61(6):2118-9. doi: 10.1002/hep.27594. Epub 2015 Apr 18. No abstract available.

23.

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Dahari H, Shteingart S, Gafanovich I, Cotler SJ, D'Amato M, Pohl RT, Weiss G, Ashkenazi YJ, Tichler T, Goldin E, Lurie Y.

Liver Int. 2015 Feb;35(2):289-94. doi: 10.1111/liv.12692. Epub 2014 Oct 10.

24.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Guedj J, Rotman Y, Cotler SJ, Koh C, Schmid P, Albrecht J, Haynes-Williams V, Liang TJ, Hoofnagle JH, Heller T, Dahari H.

Hepatology. 2014 Dec;60(6):1902-10. doi: 10.1002/hep.27357. Epub 2014 Oct 27.

25.

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H.

Antivir Ther. 2015;20(2):149-55. doi: 10.3851/IMP2806. Epub 2014 Jun 10.

26.

Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approach.

Dahari H, Cotler SJ.

Hepatology. 2014 Jun;59(6):2422-3. doi: 10.1002/hep.26772. Epub 2014 Apr 14. No abstract available.

27.

Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Rong L, Guedj J, Dahari H, Perelson AS.

Antivir Ther. 2014;19(5):469-77. doi: 10.3851/IMP2725. Epub 2014 Jan 16.

28.

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.

Guedj J, Dahari H, Uprichard SL, Perelson AS.

Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):397-9. doi: 10.1586/17474124.2013.811050. No abstract available.

29.

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.

Rong L, Guedj J, Dahari H, Coffield DJ Jr, Levi M, Smith P, Perelson AS.

PLoS Comput Biol. 2013;9(3):e1002959. doi: 10.1371/journal.pcbi.1002959. Epub 2013 Mar 14.

30.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.

31.

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Rotman Y, Noureddin M, Feld JJ, Guedj J, Witthaus M, Han H, Park YJ, Park SH, Heller T, Ghany MG, Doo E, Koh C, Abdalla A, Gara N, Sarkar S, Thomas E, Ahlenstiel G, Edlich B, Titerence R, Hogdal L, Rehermann B, Dahari H, Perelson AS, Hoofnagle JH, Liang TJ.

Gut. 2014 Jan;63(1):161-9. doi: 10.1136/gutjnl-2012-303852. Epub 2013 Feb 8.

32.

Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection.

Zhang J, Lipton HL, Perelson AS, Dahari H.

J Virol. 2013 Apr;87(7):4052-9. doi: 10.1128/JVI.03395-12. Epub 2013 Jan 30.

33.

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.

Dahari H, Cotler SJ, Layden TJ, Perelson AS.

J Hepatol. 2013 Apr;58(4):840-2. doi: 10.1016/j.jhep.2012.08.029. Epub 2012 Dec 13. No abstract available.

34.

Silymarin for HCV infection.

Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM.

Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25. Review.

35.

Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS.

J Hepatol. 2012 May;56(5):1019-24. doi: 10.1016/j.jhep.2011.12.012. Epub 2012 Jan 13.

36.

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Dahari H, Guedj J, Perelson AS, Layden TJ.

Curr Hepat Rep. 2011 Jul 2;10(3):214-227.

37.

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).

Guedj J, Dahari H, Shudo E, Smith P, Perelson AS.

Hepatology. 2012 Apr;55(4):1030-7. doi: 10.1002/hep.24788. Epub 2012 Feb 15.

38.

Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy.

Guedj J, Dahari H, Perelson AS.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E302; author reply E303. doi: 10.1073/pnas.1104149108. Epub 2011 Jun 30. No abstract available.

39.

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.

Dahari H, Guedj J, Perelson AS.

Hepatology. 2011 Aug;54(2):749. doi: 10.1002/hep.24310. Epub 2011 Jun 27. No abstract available.

40.

Hepatocyte proliferation and hepatitis C virus kinetics during treatment.

Dahari H, Rong L, Layden TJ, Cotler SJ.

Clin Pharmacol Ther. 2011 Mar;89(3):353-4. doi: 10.1038/clpt.2010.238. Epub 2011 Jan 26. No abstract available.

41.

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):95-9. doi: 10.1097/QAI.0b013e3182020596.

42.

The rate of hepatitis C virus infection initiation in vitro is directly related to particle density.

Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL.

Virology. 2010 Nov 10;407(1):110-9. doi: 10.1016/j.virol.2010.07.026. Epub 2010 Aug 25.

43.

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.

Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, Layden TJ, Cotler SJ, Barone AA.

J Viral Hepat. 2011 Apr;18(4):e52-60. doi: 10.1111/j.1365-2893.2010.01358.x.

44.

A perspective on modelling hepatitis C virus infection.

Guedj J, Rong L, Dahari H, Perelson AS.

J Viral Hepat. 2010 Dec;17(12):825-33. doi: 10.1111/j.1365-2893.2010.01348.x. Epub 2010 Aug 15. Review.

45.

Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.

Dahari H, Feinstone SM, Major ME.

Gastroenterology. 2010 Sep;139(3):965-74. doi: 10.1053/j.gastro.2010.05.077. Epub 2010 Jun 2.

46.

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.

Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, Dagan S, Naoumov NV.

Hepatology. 2010 Sep;52(3):875-85. doi: 10.1002/hep.23778.

47.

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU.

J Hepatol. 2010 Sep;53(3):460-7. doi: 10.1016/j.jhep.2010.03.019. Epub 2010 May 27.

48.

Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Rong L, Dahari H, Ribeiro RM, Perelson AS.

Sci Transl Med. 2010 May 5;2(30):30ra32. doi: 10.1126/scitranslmed.3000544.

49.

Thiazole antibiotics against breast cancer.

Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimo AV, Tonetti DA, Gartel AL.

Cell Cycle. 2010 Mar 15;9(6):1214-7. Epub 2010 Mar 15. No abstract available.

PMID:
20410687
50.

Supplemental Content

Loading ...
Support Center